Table 1.
Clinical and demographic characteristics of included patients
| Characteristica | All patients | Patients with 4.5 g PIP/TAZ three times daily | Patients with 4.5 g PIP/TAZ two times daily |
|---|---|---|---|
| (n = 60) | (n = 45) | (n = 15) | |
| Female/male (n/n) | 17/43 | 13/32 | 4/11 |
| Age (years) | 63 (54–75) | 63 (55–74) | 64 (54–78) |
| BMI (kg/m2) | 27 (24–29) | 26 (23–29) | 29 (26–31) |
| Severity scores | |||
| APACHE II score | 24 (18–31) | 24 (17–32) | 24 (18–29) |
| SOFA score | 11 (9–14) | 11 (9–13) | 12 (11–17) |
| Laboratory values | |||
| CrCl (mL/min) | 60 (24–119) | 70 (40–130) | 11 (6–19) |
| Organ transplantation (n) | |||
| Lung | 7 | 6 | 1 |
| Liver | 8 | 4 | 4 |
| Special treatments (n) | |||
| RRT patients | 10 | 7 | 3 |
| ECLA | 3 | 3 | 0 |
| Site of infection (n) | |||
| Pneumonia | 36 | 27 | 9 |
| Peritonitis | 7 | 4 | 3 |
| Catheter associated | 5 | 4 | 1 |
| Others | 12 | 10 | 2 |
| Presence of ARDS (n) | 12 | 11 | 1 |
PIP/TAZ piperacillin-tazobactam, BMI body mass index, APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA Sequential Organ Failure Assessment, CrCl creatinine clearance of patients without renal replacement therapy, RRT renal replacement therapy, ECLA extracorporeal lung assist, ARDS acute respiratory distress syndrome
aData from day 1 are presented as median (interquartile range) unless otherwise specified